Hepatic Radiation Toxicity: Avoidance and Amelioration
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The refinement of radiation therapy and radioembolization techniques has led to a resurgent interest in radiation-induced liver disease (RILD). Awareness of technical and clinical parameters that influence the chance of RILD is important to guide patient selection and toxicity minimization strategies. “Classic” RILD is characterized by anicteric ascites and hepatomegaly, and is unlikely to occur after a mean liver dose of approximately 30 Gy in conventional fractionation. By maintaining a low mean liver dose and sparing a “critical volume” of liver from radiation, stereotactic delivery techniques allow for the safe administration of higher tumor doses. Caution must be exercised for patients with hepatocellular carcinoma or pre-existing liver disease (e.g., Child-Pugh score of B or C), since they are more susceptible to RILD that can manifest in a non-classic pattern. Although no pharmacologic interventions have yet been proven to mitigate RILD, preclinical research demonstrates the potential for therapies targeting TGF-β and for transplantation of stem cells, hepatocytes, and liver progenitor cells as strategies that may restore liver function. Also, in the clinical setting of veno-occlusive liver disease following high-dose chemotherapy, agents with fibrinolytic and antithrombotic properties can reverse liver failure, suggesting a possible role in the setting of RILD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“Stellate cells and have multiple functions, including, participation in the regeneration of hepatocytes, secretion of lipoproteins, growth factors, and cytokines that play a key role in modulating inflammation and fibrosis [30,31].”
BackgroundHighly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Strigari, L., Sciuto, R., Rea, S., Carpanese, L., Pizzi, G., Soriani, A., Iaccarino, G., Benassi, M., Ettorre, G. M., & Maini, C. L. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.075861 · Cited by 239
Cited by
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
Radiation-induced liver disease: current understanding and future perspectives
Kim, J., & Jung, Y. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.85 · Cited by 260
Metadata
- Authors
- Guha, C., & Kavanagh, B. D.
- Venue
- Seminars in Radiation Oncology
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 21
- Issue
- 4
- Pages
- 256-263
- ISSN
- 1053-4296 (ISSN-L)
- OpenAlex
- W1969529822
- Cited by
- 222
- References
- 4
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatic Radiation Toxicity: Avoidance and Amelioration. https://app.cochat.ai/papers/10.1016/j.semradonc.2011.05.003
- The paper
- Guha, C., & Kavanagh, B. D. (2011). Hepatic Radiation Toxicity: Avoidance and Amelioration. Seminars in Radiation Oncology. https://doi.org/10.1016/j.semradonc.2011.05.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.